We are live on ! Find out more
ISEE

IVERIC bio, Inc. Common Stock

Delisted

ISEE was delisted on the 10th of July, 2023.

213 hedge funds and large institutions have $2.31B invested in IVERIC bio, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 57 funds opening new positions, 69 increasing their positions, 63 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

162% more call options, than puts

Call options by funds: $186M | Put options by funds: $70.8M

107% more capital invested

Capital invested by funds: $1.11B → $2.31B (+$1.2B)

104% more first-time investments, than exits

New positions opened: 57 | Existing positions closed: 28

43% more funds holding in top 10

Funds holding in top 10: 710 (+3)

16% more funds holding

Funds holding: 184213 (+29)

10% more repeat investments, than reductions

Existing positions increased: 69 | Existing positions reduced: 63

Holders
213
Holders Change
+29
Holders Change %
+15.76%
% of All Funds
3.67%
Holding in Top 10
10
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+42.86%
% of All Funds
0.17%
New
57
Increased
69
Reduced
63
Closed
28
Calls
$186M
Puts
$70.8M
Net Calls
+$115M
Net Calls Change
+$96.9M
Name Holding Trade Value Shares
Change
Change in
Stake
GTCM
176
Gyon Technologies Capital Management
New Jersey
$238K -$395K -30,057 -69%
Zurich Cantonal Bank
177
Zurich Cantonal Bank
Switzerland
$231K
WG
178
Winton Group
United Kingdom
$223K -$159K -12,115 -49%
RWP
179
RWA Wealth Partners
Massachusetts
$212K +$15.1K +1,148 +11%
Verition Fund Management
180
Verition Fund Management
Connecticut
$203K +$149K +11,315 New
VEA
181
Virtus ETF Advisers
New York
$199K +$1.02K +78 +0.7%
TSS
182
Two Sigma Securities
New York
$197K +$144K +10,954 New
AFG
183
Allegheny Financial Group
Pennsylvania
$188K
Amundi
184
Amundi
France
$187K
TFA
185
Toth Financial Advisory
Virginia
$179K
AIP
186
Ameritas Investment Partners
Nebraska
$159K
Royal Bank of Canada
187
Royal Bank of Canada
Ontario, Canada
$158K +$73.8K +5,620 +177%
TRCT
188
Tower Research Capital (TRC)
New York
$156K -$345K -26,311 -75%
Macquarie Group
189
Macquarie Group
Australia
$144K -$13.5K -1,027 -13%
MLICM
190
Metropolitan Life Insurance Company (MetLife)
New York
$135K
Parallax Volatility Advisers
191
Parallax Volatility Advisers
California
$125K -$1.25M -95,080 -93%
Nisa Investment Advisors
192
Nisa Investment Advisors
Missouri
$110K +$1.08K +82 +2%
CAC
193
Cowen and Company
New York
$109K +$550K +41,900 New
Allspring Global Investments
194
Allspring Global Investments
North Carolina
$96K -$58.7K -4,472 -45%
DFCM
195
Dark Forest Capital Management
Puerto Rico
$93K +$53.9K +4,103 +374%
Canada Life
196
Canada Life
Manitoba, Canada
$85K +$20.3K +1,547 +48%
CG
197
Cutler Group
California
$62K +$45.7K +3,482 New
EWM
198
Endurance Wealth Management
Rhode Island
$48K
PCH
199
Polar Capital Holdings
United Kingdom
$33.5K
BBHC
200
Brown Brothers Harriman & Co
New York
$24K

ISEE Hedge Fund Activity: Q3 2022 in Review

213 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in IVERIC bio, Inc. Common Stock (ISEE) for Q3 2022, worth a combined $2.31B — up 107% from $1.11B a quarter earlier.

Buyers outnumbered sellers: 57 funds opened new ISEE positions and 28 closed out — a net gain of 29 holders — while 69 added to existing stakes and 63 trimmed.

The largest buyer was RTW Investments, opening a new position worth an estimated $47.6M. The largest seller was Vivo Capital, cutting an estimated $62.4M.

  • 213 institutional investors held IVERIC bio, Inc. Common Stock (ISEE) as of Q3 2022, up from 184 in Q2 2022.
  • Funds reported $2.31B of IVERIC bio, Inc. Common Stock stock for Q3 2022, up 107% quarter-over-quarter.
  • 57 funds opened new IVERIC bio, Inc. Common Stock positions in Q3 2022 and 28 closed out, a net change of +29 holders.
  • The largest IVERIC bio, Inc. Common Stock buyer in Q3 2022 was RTW Investments, an estimated $47.6M added.
  • The largest IVERIC bio, Inc. Common Stock seller in Q3 2022 was Vivo Capital, an estimated $62.4M sold.

Based on aggregated 13F filings for Q3 2022.